NGM Biopharmaceuticals (NYSE:NGM) issued its quarterly earnings data on Monday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.71, Bloomberg Earnings reports. The firm had revenue of $25.34 million for the quarter, compared to the consensus estimate of $19.00 million.
NYSE NGM opened at $13.50 on Tuesday. NGM Biopharmaceuticals has a 1-year low of $12.00 and a 1-year high of $18.75. The company has a 50 day simple moving average of $13.98.
A number of equities research analysts have recently issued reports on the company. Citigroup assumed coverage on NGM Biopharmaceuticals in a report on Monday, April 29th. They set a “buy” rating and a $29.00 price objective for the company. Stifel Nicolaus assumed coverage on shares of NGM Biopharmaceuticals in a research report on Monday, June 24th. They issued a “buy” rating and a $26.00 price target for the company. Goldman Sachs Group assumed coverage on shares of NGM Biopharmaceuticals in a research report on Monday, April 29th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Cowen reiterated a “buy” rating and issued a $25.00 price target on shares of NGM Biopharmaceuticals in a research report on Monday, May 20th.
NGM Biopharmaceuticals Company Profile
NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.
See Also: Equity Income
Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.